By Sabela Ojea

AstraZeneca PLC said Friday that its Ultomiris drug has been approved in the European Union for the treatment of adults with the rare disease generalized myasthenia gravis.

The Anglo-Swedish pharma giant said that Ultomiris may reduce treatment burden with dosing every eight weeks, it said, adding that the drug also proved an improvement in activities of daily living.

Generalized myasthenia gravis is a rare autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness, AstraZeneca said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

September 23, 2022 02:27 ET (06:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Astrazeneca.